© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
March 02, 2020
PARP inhibitors are novel therapies with indication focused on ovarian cancer; however, new agents are being studied for other cancers as well.
January 01, 2020
It is impossible to assert that patients will not experience any adverse events while on targeted therapy. Communicating and addressing effective mitigation strategies to ameliorate these adverse events can lead to improved clinical outcomes.